Your session is about to expire
← Back to Search
Nivolumab for Brain Cancer
Study Summary
This trial is testing nivolumab to see if it stops tumor growth and prolongs the time that the tumor is controlled in adults with IDH1 or IDH2 mutated gliomas.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 541 Patients • NCT02041533Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any uncontrolled illnesses.I can care for myself but may need occasional help.I have received immune therapy in the past.My organs and bone marrow are working well.I am taking more than 1 mg of dexamethasone or its equivalent daily.My tumor mutation burden was tested at NIH.I am 18 years old or older.My glioma has come back and has an IDH mutation.I have been cancer-free for at least 3 years from a previous cancer.
- Group 1: 1/Nivolumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What safety profile has been observed with Nivolumab usage?
"The safety of Nivolumab is rated at a 2 on the scale, as it has been tested for efficacy but not to its full extent. There is however some data available that corroborates its safety."
In what medical circumstances is Nivolumab typically recommended?
"Nivolumab is regularly used to combat malignant neoplasms, but has also proven successful in treating forms of melanoma, squamous cell carcinoma, and esophageal adenocarcinomas which are not operable."
Is this research the inaugural endeavor of its kind?
"Since 2012, Ono Pharmaceutical Co. Ltd has conducted 252 trials for Nivolumab across 49 countries and 2356 cities. Currently there are 718 active studies of this investigational drug, with the first trial completed in its Phase 1 & 2 approval stage involving 659 patients."
Is recruitment still underway for this experiment?
"According to the clinicaltrials.gov database, this research study is currently accepting trial participants. The first posting of this medical project was on March 27th 2019, with its latest edit being in November 19th 2022."
Has Nivolumab been the focus of previous research initiatives?
"Presently, there are 718 clinical trials exploring the efficacy of Nivolumab. Of those live studies, 82 have reached Phase 3 status. While Basel in BE is a major site for such research, 40285 different sites around the world are offering this treatment to their patients."
How many participants are accepted in this research endeavor?
"Affirmative, according to clinicaltrials.gov the study is still recruiting participants since its initial posting on March 27th 2019 and last update of November 19th 2022. At present, 95 individuals are sought from a single centre."
Share this study with friends
Copy Link
Messenger